Caxton Associates (UK)’s Cidara Therapeutics CDTX Stock Holding History

Caxton Associates (UK)’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,821	Closed	-$15.2M	–	805
2025 Q4	$15.2M	Buy	+68,821	New	+$11.1M	0.3%	41

Caxton Associates (UK)'s CDTX Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 68,821 shares — an estimated $15.2M sold.

Caxton Associates (UK) first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $15.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Caxton Associates (UK) reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Caxton Associates (UK) sold 68,821 Cidara Therapeutics shares in Q1 2026, an estimated $15.2M.
Caxton Associates (UK) first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Caxton Associates (UK)'s Cidara Therapeutics position peaked at $15.2M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.